AIM ImmunoTech (AIM) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 12, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,841,656

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 15,264	$ 27,053
Marketable investments	7,167	7,137
Funds receivable from New Jersey net operating loss	48	1,676
Prepaid expenses and other current assets	263	455
Total current assets	22,742	36,321
Property and equipment, net	136	195
Right of use asset, net	727	829
Patent and trademark rights, net	2,154	1,941
Other assets	2,102	1,202
Total assets	27,861	40,488
Current liabilities:
Accounts payable	2,788	377
Accrued expenses	1,721	806
Current portion of operating lease liability	207	178
Total current liabilities	4,716	1,361
Long-term liabilities:
Operating lease liability	543	659
Commitments and contingencies (Notes 12 and 13)
Stockholders’ equity:
Preferred Stock, $0.01 par value, 5,000,000 authorized shares, inclusive of the following:
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 48,797,450 and 48,084,287 (including 133,333 and 561,104 of unvested stock awards) as of September 30, 2023 and December 31, 2022, respectively	48	48
Additional paid-in capital	418,796	418,270
Accumulated deficit	(396,932)	(380,546)
Total stockholders’ equity	22,602	38,468
Total liabilities and stockholders’ equity	27,861	40,488
Series A Junior Participating Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, $0.01 par value, 5,000,000 authorized shares, inclusive of the following:
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, $0.01 par value, 5,000,000 authorized shares, inclusive of the following:	$ 690	$ 696

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, stated value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	48,797,450	48,084,287
Common stock, shares outstanding	48,797,450	48,084,287
Unvested stock awards	133,333	561,104
Series A Junior Participating Preferred Stock [Member]
Preferred stock, stated value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,000,000	250,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Series B Convertible Preferred Stock [Member]
Preferred stock, stated value	$ 1,000	$ 1,000
Preferred stock, shares authorized	10,000
Preferred stock, shares issued	690	696
Preferred stock, shares outstanding	690	696

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Clinical treatment programs - US	$ 46	$ 21	$ 137	$ 85
Total Revenues	46	21	137	85
Costs and Expenses:
Production costs	30		30
Research and development	2,734	1,372	7,739	4,883
General and administrative	5,439	5,170	10,280	9,569
Total Costs and Expenses	8,203	6,542	18,049	14,452
Operating Loss	(8,157)	(6,521)	(17,912)	(14,367)
Loss on investments	(310)	(365)	(201)	(1,769)
Interest and other income	294	172	811	296
Gain on sale of fixed assets	39		16
Redeemable warrants valuation adjustment		1		35
Gain on sale of income tax operating losses	318	328	900	749
Net Loss	$ (7,816)	$ (6,385)	$ (16,386)	$ (15,056)
Basic loss per share	$ (0.16)	$ (0.13)	$ (0.34)	$ (0.31)
Diluted loss per share	$ (0.16)	$ (0.13)	$ (0.34)	$ (0.31)
Weighted average shares outstanding basic	48,635,165	48,079,210	48,483,802	48,036,559
Weighted average shares outstanding diluted	48,635,165	48,079,210	48,483,802	48,036,559

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021		$ 48	$ 417,217		$ (361,101)	$ 56,879
Balance, shares at Dec. 31, 2021	715	47,994,672
Common stock issuance, net of costs			80			80
Common stock issuance, net of costs, shares		86,817
Equity-based compensation			792			792
Net comprehensive loss					(15,056)	(15,056)
Cashless warrant conversion
Cashless warrant conversion, shares		558
Series B preferred shares converted to common shares			2
Balance, shares	(2)	228
Ending balance, value at Sep. 30, 2022		$ 48	418,091		(376,157)	42,695
Balance, shares at Sep. 30, 2022	713	48,082,275
Beginning balance, value at Jun. 30, 2022		$ 48	417,791		(369,772)	48,780
Balance, shares at Jun. 30, 2022	713	48,048,822
Common stock issuance, net of costs			25			25
Common stock issuance, net of costs, shares		32,895
Equity-based compensation			275			275
Net comprehensive loss					(6,385)	(6,385)
Cashless warrant conversion
Cashless warrant conversion, shares		558
Ending balance, value at Sep. 30, 2022		$ 48	418,091		(376,157)	42,695
Balance, shares at Sep. 30, 2022	713	48,082,275
Beginning balance, value at Dec. 31, 2022		$ 48	418,270		(380,546)	38,468
Balance, shares at Dec. 31, 2022	696	48,084,287
Common stock issuance, net of costs			338			$ 338
Common stock issuance, net of costs, shares		712,479				327,055
Equity-based compensation			182			$ 182
Net comprehensive loss					(16,386)	(16,386)
Series B preferred shares converted to common shares			6
Balance, shares	(6)	684
Ending balance, value at Sep. 30, 2023		$ 48	418,796		(396,932)	22,602
Balance, shares at Sep. 30, 2023	690	48,797,450
Beginning balance, value at Jun. 30, 2023		$ 48	418,513		(389,116)	30,135
Balance, shares at Jun. 30, 2023	690	48,419,491
Common stock issuance, net of costs			233			233
Common stock issuance, net of costs, shares		377,959
Equity-based compensation			50			50
Net comprehensive loss					(7,816)	(7,816)
Ending balance, value at Sep. 30, 2023		$ 48	$ 418,796		$ (396,932)	$ 22,602
Balance, shares at Sep. 30, 2023	690	48,797,450

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (16,386,000)	$ (15,056,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	30,000	29,000
Redeemable warrants valuation adjustment		(35,000)
Abandonment of patent and trademark rights	14,000
Amortization of patent, trademark rights	150,000	57,000
Non-cash lease expense	151,000	(717,000)
Gain on sale of income tax operating losses	(900,000)	(749,000)
Equity-based compensation	182,000	792,000
Loss on sale of investments	201,000	1,768,000
Change in assets and liabilities:
Other receivables	(9,000)
Funds receivable from New Jersey net operating loss	1,676,000	1,641,000
Prepaid expenses and other current assets and other non-current assets	192,000	(500,000)
Lease liability	(136,000)	717,000
Other assets		(73,000)
Accounts payable	2,411,000	758,000
Accrued expenses	915,000	1,329,000
Net cash used in operating activities	(11,509,000)	(10,039,000)
Cash flows from investing activities:
Proceeds from sale of marketable investments	924,000	9,082,000
Purchase of marketable investments	(1,155,000)	(1,661,000)
(Purchase of) Proceeds from sale of property and equipment	(10,000)	300,000
Purchase of patent and trademark rights	(377,000)	(96,000)
Net cash (used in) provided by investing activities	(618,000)	7,625,000
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs	338,000	80,000
Net cash provided by financing activities	338,000	80,000
Net decrease in cash and cash equivalents	(11,789,000)	(2,334,000)
Cash and cash equivalents at beginning of period	27,053,000	32,093,000
Cash and cash equivalents at end of period	15,264,000	29,759,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Operating lease liability arising from obtaining right of use asset	49,000	717,000
Unrealized loss on marketable investments	(71,000)	(1,170,000)
Conversion of Series B preferred	$ 6,000	$ 2,000

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection (Interferon alfa). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company’s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Company is currently proceeding primarily in four areas: ● Conducting a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients. ● Evaluating Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors. ● Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. ● Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or Post-COVID conditions of fatigue. The Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (“EMA”), which trials support a potential future NDA. However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues. AIM’s business plan requires one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen and its Active Pharmaceutical Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly C12U polynucleotides, respectively. Additionally, our relationship with Polysciences Inc. (“Polysciences”) continues and R&D development of polymer manufacture is ongoing. In the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2022, and 2021, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 31, 2023. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, equity-based compensation calculations, fair value of warrants, and contingency accruals.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Note 2: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 2,763,020 2,445,805

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 3: Equity-Based Compensation The 2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the “2018 Equity Incentive Plan”) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 250,000 44,299 685,012 956,660 960,976 968,389 10,865,336 10 26,324 9.68 10 23 9.68 ten years 27,570 9.68 ten years 400,000 2.77 3.07 ten years 613,512 1.11 1.71 ten years 850,000 0.31 0.71 ten years no The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. During the nine months ended September 30, 2023, there were no 300,000 Employee stock option activity during the three months ended September 30, 2023, was as follows: Stock option activity for employees: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding June 30, 2023 2,019,551 $ 3.01 8.36 $ — Granted — — — — Forfeited — — — — Expired (11,113 ) 2.90 8.41 — Outstanding September 30, 2023 2,008,438 $ 2.90 8.41 $ — Vested and expected to vest September 30, 2023 2,008,438 $ 2.90 8.41 $ — Exercisable September 30, 2023 1,941,772 $ 1.98 6.52 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested June 30, 2023 166,664 $ 9.17 6.41 $ — Granted — — — — Expired (11,111 ) 2.90 8.41 — Vested (88,887 ) 1.98 6.52 — Unvested September 30, 2023 66,666 $ 14.60 17.04 $ — Stock option activity for non-employees: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding June 30, 2023 579,032 $ 3.09 8.36 $ — Granted — — — — Forfeited — — — — Expired (53,977 ) 1.62 8.67 — Outstanding September 30, 2023 525,055 $ 1.62 8.67 $ — Vested and expected to vest September 30, 2023 525,055 $ 1.62 8.67 $ — Exercisable September 30, 2023 458,388 $ 2.99 10.16 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested June 30, 2023 66,666 $ 9.45 4.59 $ — Granted — — — — Expired (54,100 ) 1.62 8.67 — Vested 54,101 2.99 10.16 — Unvested September 30, 2023 66,667 $ 6.75 4.28 $ — Equity-based compensation expense was approximately $ 50,000 275,000 Employee stock option activity during the nine months ended September 30, 2023, was as follows: Stock option activity for employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2023 2,020,214 $ 3.01 8.86 $ — Granted — — — — Forfeited — — — — Expired (11,776 ) 2.90 12.81 — Outstanding September 30, 2023 2,008,438 $ 2.90 8.41 $ — Vested and expected to vest September 30, 2023 2,008,438 $ 2.90 8.41 $ — Exercisable September 30, 2023 1,941,772 $ 1.98 6.52 $ — Unvested stock option activity for employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2023 392,326 $ .80 8.86 $ — Granted — — — — Expired (11,776 ) 2.90 8.41 — Vested (313,884 ) 1.98 6.52 — Unvested September 30, 2023 66,666 $ 14.60 17.04 $ — Stock option activity for non-employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2023 579,155 $ 3.09 7.93 $ — Granted — — — — Forfeited — — — — Expired (54,100 ) 1.62 8.67 — Outstanding September 30, 2023 525,055 $ 1.62 8.67 $ — Vested and expected to vest September 30, 2023 525,055 $ 1.62 8.67 $ — Exercisable September 30, 2023 458,388 $ 2.99 10.16 $ — Unvested stock option activity for non-employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2023 166,789 $ 4.05 9.49 $ — Granted — — — — Expired (54,223 ) 1.62 8.67 — Vested (45,899 ) 2.99 10.16 — Unvested September 30, 2023 66,667 $ 6.75 4.28 $ — Equity-based compensation expense was approximately $ 182,000 792,000 As of September 30, 2023, and 2022, there was approximately $ 35,000 179,000 no

Marketable Investments

Marketable Investments	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Investments	Note 4: Marketable Investments Marketable investments consist of mutual funds. As of September 30, 2023 and December 31, 2022, it was determined that none of the marketable investments had an other-than-temporary impairment. As of September 30, 2023 and December 31, 2022, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 11: Fair Value). As of September 30, 2023, and December 31, 2022 the Company held $ 7,167,000 7,137,000 Mutual Funds classified as available for sale consisted of: Schedule of Available of Sale September 30, 2023 (in thousands) Securities Fair Value Short-Term Investments Mutual Funds $ 7,167 $ 7,167 Totals $ 7,167 $ 7,167 Schedule of Equity Securities For the Three months Ended September 30, 2023 Securities Net losses recognized during the period on equity securities $ (309 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (42 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (267 ) For the Nine months Ended September 30, 2023 (in thousands) Securities Net losses recognized during the period on equity securities $ (201 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (130 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (71 ) Mutual Funds classified as available for sale consisted of: December 31, 2022 (in thousands) Securities Fair Value Short-Term Investments Mutual Funds $ 7,137 $ 7,137 Totals $ 7,137 $ 7,137 For the Three months Ended September 30, 2022 Securities Net losses recognized during the period on equity securities $ (365 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (15 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (350 ) For the Nine months Ended September 30, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (1,768 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (598 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (1,170 )

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 5: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses September 30, 2023 December 31, 2022 (in thousands) September 30, 2023 December 31, 2022 Compensation $ 29 $ 1 Professional fees 1,459 492 Clinical trial expenses 127 110 Other expenses 106 203 Accrued expenses $ 1,721 $ 806

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 6: Property and Equipment, net Schedule of Property and Equipment September 30, 2023 December 31, 2022 (in thousands) September 30, 2023 December 31, 2022 Furniture, fixtures, and equipment 1,555 2,233 Less: accumulated depreciation (1,419 ) (2,038 ) Property and equipment, net $ 136 $ 195 Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to ten years. Depreciation expense for the nine months ending September 30, 2023 and September 30, 2022 was $ 30,000 29,000

Patents, and Trademark Rights,

Patents, and Trademark Rights, Net	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Patents, and Trademark Rights, Net	Note 7: Patents, and Trademark Rights, Net The table below presents the changes in patent and trademark rights (in thousands): Schedule of Patents, Trademark Rights December 31, 2022 $ 1,941 Acquisitions 377 Abandonments and expirations (14 ) Amortization (150 ) September 30, 2023 $ 2,154 Patents and trademarks are stated at cost. Patents and trademarks are amortized using the straight-line method over an estimated useful life of 17 10 Amortization of patents and trademarks for each of the next five years and thereafter is as follows (in thousands): Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2023 $ 58 2024 225 2025 217 2026 215 2027 194 Thereafter 1,245 Total $ 2,154

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 8: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 4,000,000 10,000 Series A Junior Participating Preferred Stock On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to 4,000,000 250,000 Series B Convertible Preferred Stock The series of preferred stock shall be designated as its Series B Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 10,000 . Each share of Preferred Stock shall have a par value of $ 0.01 per share and a stated value equal to $ 1,000 (the “Stated Value”). The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of the shares of Preferred Stock. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $ 0.20 Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 five years 4,700,000 6 As of September 30, 2023, and December 31, 2022, the Company had 690 696 114 (b) Common Stock and Equity Finances The Company has authorized shares of 350,000,000 8,000,000 350,000,000 As of September 30, 2023, and December 31, 2022, there were 48,797,450 48,084,287 Employee Stock Purchase Plan (Not equity compensation) On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 During the nine months ended September 30, 2023, the Company issued a total of 385,424 0.31 0.67 135,000 During the nine months ended September 30, 2022, the Company issued a total of 87,045 0.72 1.02 80,000 Warrants (Rights offering) On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 a Representative’s Warrant to purchase up to an aggregate of 266,665 . The shares of Common Stock and Warrants were sold at a combined Offering price of $ 0.90 0.99 0.899 4.99 0.001 7,200,000 , 2020, 1,870,000 8,873,960 266,665 264,000 46,000 15,000 Equity Distribution Agreement On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 8.5 3.0 327,055 209,000 3.0 6,271 Rights Plan On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”).

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2023
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 9 Cash and Cash Equivalents AIM considers all highly liquid interest-earning investments with an original maturity of three months or less at the date of purchase to be cash equivalents.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2023
Recent Accounting Pronouncements
Recent Accounting Pronouncements	Note 10: Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. Accounting pronouncements issued by the FASB since filing the Annual Report on Form 10-K for the year ended December 31, 2022 did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value	Note 11: Fair Value Fair Value The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: 1. Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market. 2. Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. 3. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of September 30, 2023, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of September 30, 2023 Total Level 1 Level 2 Level 3 Assets: Cash equivalent $ 14,110 $ 14,110 $ — $ — Marketable investments $ 7,167 $ 7,167 $ — $ — As of December 31, 2022 Total Level 1 Level 2 Level 3 Assets: Cash equivalent $ 25,180 $ 25,180 $ — $ — Marketable investments $ 7,137 $ 7,137 $ — $ — The Company’s cash balances are representative of their fair values as these balances are comprised of deposits available on demand. For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1). The Company also has certain redeemable warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the redeemable warrants (“Redeemable Warrants”) related to the Company’s April 2018 and March 2019 common stock and warrant issuance, are calculated using a Monte Carlo Simulation (Level 3). The Company recomputes the fair value of the Redeemable Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The Company utilized the following assumptions to estimate the fair value of the April 2018 Redeemable Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants September 30, 2023 December 31, 2022 Underlying price per share $ 0.46 $ 0.31 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 5.55 % 4.74 % Expected holding period 0.07 0.81 Expected volatility 85 % 75 % Expected dividend yield — — Warrants measurement input — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Redeemable Warrants: September 30, 2023 December 31, 2022 Underlying price per share $ 0.46 $ 0.31 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 5.53 % 4.67 % Expected holding period 0.44 1.19 Expected volatility 80 % 70 % Expected dividend yield — — Warrants measurement input — — The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: (i) Risk-Free Interest Rate (ii) Expected Holding Period (iii) Expected Volatility (iv) Expected Dividend Yield (v) Expected Probability of a Fundamental Transaction. 1. The Company only has one product that is FDA approved but is currently not available for commercial sales. 2. The Company will have to perform additional clinical trials for FDA approval of its flagship product. 3. Industry and market conditions continue to include uncertainty, adding risk to any transaction. 4. The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development. 5. The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and 6. The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer. With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 % The Monte Carlo Simulation has incorporated a 5.0 (vi) Expected Timing of Announcement of a Fundamental Transaction. (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction 100 (viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction (ix) Expected Time Between Announcement and Consummation of a Fundamental Transaction. While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input for the relevant period input change. As of September 30, 2023 and December 31, 2022 there was no carrying amount and estimated fair value of the above Redeemable Warrants.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	Note 12: Leases The Company leases office and storage space, and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 5 At contract inception, utilizing the guidance of ASC 842 “ Leases The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion is recognized as variable lease expenses as incurred. At lease inception, lease-related assets and liabilities are measured at the present value of future lease payments over the lease term. For leases that do not provide an implicit rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate the present value of future payments. Leased assets are disclosed as Right of Use assets on the Company’s consolidated balance sheet and are amortized over the expected useful life of the lease. Lease liabilities are separately disclosed as a current and non-current portion on the Company’s consolidated balance sheet. Short term leases with an initial term of 12 months or less are not presented on the balance sheet with expense recognized as incurred. The Company entered into a Lease Agreement for a term of five years September 14, 2020 1,415 On June 13, 2018, the Company entered into a Lease Agreement for a term of six years July 1, 2018 3,000 3 2,100 2,785 On May 1, 2019, the Company entered into a Lease Agreement for a term of three years May 1, 2019 3,000 2,500 2,850 May 1, 2023 3,000 May 1, 2024 On February 17, 2022, the Company entered into a Lease Agreement for a term of two years March 1, 2022 322 On June 16, 2022, the Company entered into a Lease Agreement for a term of five years July 1, 2022 5,210 3 15,630 18,118 On December 9, 2022, the Company entered into a Lease Agreement for a term of two years April 1, 2023 470 6 1,645 1,744 The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 9 50 43 42 The Company’s weighted average incremental borrowing rate for its leases was 10 Future minimum lease payments as of September 30, 2023, are as follows (in thousands): Schedule of Operating Lease Future Payments Year Ending December 31, 2023 $ 73 2024 264 2025 221 2026 200 2027 133 Less imputed interest (141 ) Total $ 750 As of September 30, 2023, and December 31, 2022, the balance of the right of use assets was $ 727,000 829,000 750,000 837,000 230,000 75,000 198,000 8,000

Research, Consulting and Supply

Research, Consulting and Supply Agreements	9 Months Ended
	Sep. 30, 2023
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 13: Research, Consulting and Supply Agreements The following represent companies with which AIM has active contracts that it paid toward during the nine months ended September 30, 2023. Amarex Clinical Research LLC AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the nine months ended September 30, 2023, the Company paid $ 1,266,800 ● Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $ 8.4 1.0 4.6 ○ During the nine months ended September 30, 2023, the Company paid approximately $ 350,600 ● Post-COVID Conditions - On September 13, 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $ 6.4 125,470 4.4 ○ During the nine months ended September 30, 2023, the Company paid approximately $ 916,200 hVIVO Services Limited In July 2021, the Company executed a Reservation and Start-Up Agreement (the “Agreement”) with hVIVO Services Limited (“hVIVO”), and subsequently signed a clinical trial agreement (“CTA”) in September. For the year ended December 31, 2021, the Company incurred an expense and paid hVIVO approximately $ 2,340,000 60,000 Impatients N.V. In 2016, the Company entered into a five-year agreement (the “Impatients Agreement”) with Impatients, N.V. (“myTomorrows”), a Netherlands-based company, for the commencement and management of an EAP in Europe and Turkey (the “Territory”) related to ME/CFS. Pursuant to the agreement, myTomorrows, as exclusive service provider and distributor in the Territory, is performing EAP activities. The agreement was automatically extended for a period of 12 months on May 20, 2021; has been automatically extended for 12 months on each subsequent May 20; and will continue to be automatically extended for periods of 12 months every May 20 until terminated or the terms of the agreement are met. ○ During the nine months ended September 30, 2023, the Company paid approximately $ 31,100 Jubilant HollisterStier Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, two lots of Ampligen consisting of more than 16,000 1,432,257 ○ During the nine months ended September 30, 2023, the Company paid approximately $ 1,432,300 Pharmaceutics International Inc. In December 2020, AIM added Pharmaceutics International Inc. (“Pii”) as a “Fill & Finish” provider to enhance AIM’s capacity to produce the drug Ampligen. This addition amplifies AIM’s manufacturing capability by providing redundancy and cost savings. The contracts augment AIM’s existing fill and finish capacity. As agreed to in the Master Services Agreement, the terms of each of AIM’s projects with Pii will be negotiated separately and defined in individual Service Contracts. For the year ended December 31, 2022, the Company had incurred an expense and paid Pii approximately $ 278,000 ○ During the nine months ended September 30, 2023, the Company paid approximately $ 55,400 Polysciences Inc. In April 2021, AIM approved a proposal from Polysciences Inc. (“Polysciences”) for the manufacture of our Poly I and Poly C12U polynucleotides and associated test methods at Polysciences’ Warrington, PA location to enhance our capacity to produce the polymer precursors to the drug Ampligen. The Company is working with Polysciences to negotiate and finalize both a Service Agreement and a Quality Agreement. For the year ended December 31, 2021, the Company incurred an expense and paid Polysciences approximately $ 250,000 ○ During the nine months ended September 30, 2023, there were no Yamasa Corporation AIM also utilizes Yamasa Corporation (“Yamasa”) for the production of raw materials required to create polymer precursors to manufacture the drug Ampligen. In March 2023, the Company submitted a work order for $ 327,730 ○ During the nine months ended September 30, 2023, there were no Sterling Pharma Solutions On December 5, 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. ○ During the nine months ended September 30, 2023, the Company paid approximately $ 357,000

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 14: Subsequent Events In the Company’s lawsuit against BioLife Plasma Services, LP, the trial court issued a ruling in March 2023 on cross Motions for Summary Judgment in which it denied all of the Company’s motions and granted defendant’s Motion to exclude evidence of future loss of profit damages. The ruling specified that AIM had properly pled and the Court was specifically allowing AIM’s damages theory to proceed on reliance damages. The Company sought reconsideration of the ruling based on its internal inconsistency with the contemporaneously issued Order which allowed only the counterclaims to proceed. In July, the Company sought appellate review of the inconsistent lower Court pretrial rulings. On September 8, 2023, the Court issued an Order in response to the Motion for Reconsideration. The Court granted the Motion, vacated its prior Order on summary judgment, and issued a new Order and Opinion. The new Order and Opinion again denied the motion for summary judgment in total, and granted the motion for summary judgment of defendants. The effect of the Order was to once again allow only the defendant’s counterclaim to proceed. On October 6, 2023, the Company sought a certification of the Court to allow immediate appeal. The Court has not ruled on the Motion. On August 8, 2023, the Company filed a motion to reconsider its lawsuit against Robert Chioini, Todd Deutsch, Jonathan Jorgl, Ted D. Kellner, Walter Lautz, Michael Rice and Franz Tudor in the Federal District Court for the Middle District of Florida (the “Federal Securities Action”). The court had dismissed the Federal Securities Action on July 10, 2023 on mootness grounds because the 2022 Annual Meeting, including the election of directors, had already occurred. The Company filed a motion for the district court to reconsider the dismissal of the Federal Securities Action. The district court denied its motion to reconsider on September 27, 2023. Separately, Mr. Lautz moved for reconsideration of the district court’s order pursuant to the Private Securities Litigation Reform Act of 1995 on August 7, 2023, and Mr. Jorgl moved for attorneys’ fees under Rule 11 on September 12, 2023. On October 10, 2023, the district court granted-in-part Mr. Lautz’s motion, postponed ruling on Mr. Jorgl’s motion and scheduled a hearing on November 2, 2023. However, after the Company filed a notice of appeal on October 27, 2023, the district court canceled the November 2, 2023 hearing and ordered the parties to meet and confer on preparing a joint statement addressing whether (1) the district court retained subject matter jurisdiction over Messrs. Lautz and Jorgl’s motions and (2) judicial economy counsels in favor of postponing a ruling on Messrs. Lautz and Jorgl’s motions pending our appeal. On August 25, 2023, Ted D. Kellner filed suit against the Company and the members of its Board in the Delaware Court of Chancery (the “2023 Delaware Litigation”). The complaint challenged (1) the Company’s adoption of amendments to the advance notice provision of its bylaws; and (2) the decision of the Board to reject Kellner’s notice of intent to nominate himself and two other candidates for election to the Board at the Company’s 2023 annual meeting of stockholders on the basis that the nomination notice failed to comply with the Company’s amended bylaws. The complaint seeks, among other things, a declaration that (1) the amendments to the Company’s bylaws were unlawful; and/or (2) the Board’s application of the amended bylaws to reject Kellner’s nomination notice was unlawful or inequitable. On September 11, 2023, the Company and the members of the Board filed an answer responding to Kellner’s complaint and filed a counterclaim. The counterclaim seeks a declaration that (1) the Company’s bylaw amendments are lawful and valid; and (2) Kellner’s nomination notice did not comply with the Company’s bylaws. Upon completion of expedited discovery and briefing, the Delaware Court of Chancery held trial from October 30, 2023 to November 1, 2023. Post-trial briefs from both parties are due on November 16, 2023, and post-trial argument is scheduled for November 21, 2023. An opinion is expected before the Company’s 2023 annual meeting of stockholders, scheduled to convene on December 1, 2023. Although Kellner is not presently seeking monetary relief of legal fees from the Company in the 2023 Delaware Litigation, if elected, his slate of purported director nominees intends to seek to reimburse Kellner and related parties’ legal fees and expenses incurred during their 2022 and 2023 proxy contests. On July 20, 2023, the Company and the Board, as the defendants, filed a motion to shift all litigation fees they incurred in connection with the Jorgl v. AIM Immunotech, Inc. et al. action to Jorgl on the basis that he brought the litigation in bad faith (the “AIM Fee Motion”). Also on July 20, 2023, Jorgl filed a motion to shift certain legal fees to the defendants that he incurred in connection with contesting a subpoena defendants served on the legal counsel that advised Jorgl in his nomination efforts, Baker & Hostetler LLP (the “Jorgl Fee Motion”). The Delaware Court of Chancery recently ruled on certain discovery motions pertaining to the AIM Fee Motion, and the parties will be negotiating a briefing schedule to complete briefing on the AIM Fee Motion and the Jorgl Fee Motion. On October 16, 2023, AIM entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to assist AIM with its BD efforts with the goal of entering into a partnership, out-license or other transaction whereby a biopharmaceutical company takes on the further development and commercialization of Ampligen with the goal of maximizing value to AIM. On October 26, 2023, by unanimous consent, the Board approved the latest Employee Stock Purchase Plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for employees: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding June 30, 2023 2,019,551 $ 3.01 8.36 $ — Granted — — — — Forfeited — — — — Expired (11,113 ) 2.90 8.41 — Outstanding September 30, 2023 2,008,438 $ 2.90 8.41 $ — Vested and expected to vest September 30, 2023 2,008,438 $ 2.90 8.41 $ — Exercisable September 30, 2023 1,941,772 $ 1.98 6.52 $ — Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2023 2,020,214 $ 3.01 8.86 $ — Granted — — — — Forfeited — — — — Expired (11,776 ) 2.90 12.81 — Outstanding September 30, 2023 2,008,438 $ 2.90 8.41 $ — Vested and expected to vest September 30, 2023 2,008,438 $ 2.90 8.41 $ — Exercisable September 30, 2023 1,941,772 $ 1.98 6.52 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested June 30, 2023 166,664 $ 9.17 6.41 $ — Granted — — — — Expired (11,111 ) 2.90 8.41 — Vested (88,887 ) 1.98 6.52 — Unvested September 30, 2023 66,666 $ 14.60 17.04 $ — Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2023 392,326 $ .80 8.86 $ — Granted — — — — Expired (11,776 ) 2.90 8.41 — Vested (313,884 ) 1.98 6.52 — Unvested September 30, 2023 66,666 $ 14.60 17.04 $ —
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for non-employees: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding June 30, 2023 579,032 $ 3.09 8.36 $ — Granted — — — — Forfeited — — — — Expired (53,977 ) 1.62 8.67 — Outstanding September 30, 2023 525,055 $ 1.62 8.67 $ — Vested and expected to vest September 30, 2023 525,055 $ 1.62 8.67 $ — Exercisable September 30, 2023 458,388 $ 2.99 10.16 $ — Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2023 579,155 $ 3.09 7.93 $ — Granted — — — — Forfeited — — — — Expired (54,100 ) 1.62 8.67 — Outstanding September 30, 2023 525,055 $ 1.62 8.67 $ — Vested and expected to vest September 30, 2023 525,055 $ 1.62 8.67 $ — Exercisable September 30, 2023 458,388 $ 2.99 10.16 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested June 30, 2023 66,666 $ 9.45 4.59 $ — Granted — — — — Expired (54,100 ) 1.62 8.67 — Vested 54,101 2.99 10.16 — Unvested September 30, 2023 66,667 $ 6.75 4.28 $ — Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2023 166,789 $ 4.05 9.49 $ — Granted — — — — Expired (54,223 ) 1.62 8.67 — Vested (45,899 ) 2.99 10.16 — Unvested September 30, 2023 66,667 $ 6.75 4.28 $ —

Marketable Investments (Tables)

Marketable Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Available of Sale	Mutual Funds classified as available for sale consisted of: Schedule of Available of Sale September 30, 2023 (in thousands) Securities Fair Value Short-Term Investments Mutual Funds $ 7,167 $ 7,167 Totals $ 7,167 $ 7,167 Mutual Funds classified as available for sale consisted of: December 31, 2022 (in thousands) Securities Fair Value Short-Term Investments Mutual Funds $ 7,137 $ 7,137 Totals $ 7,137 $ 7,137
Schedule of Equity Securities	Schedule of Equity Securities For the Three months Ended September 30, 2023 Securities Net losses recognized during the period on equity securities $ (309 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (42 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (267 ) For the Nine months Ended September 30, 2023 (in thousands) Securities Net losses recognized during the period on equity securities $ (201 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (130 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (71 ) For the Three months Ended September 30, 2022 Securities Net losses recognized during the period on equity securities $ (365 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (15 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (350 ) For the Nine months Ended September 30, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (1,768 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (598 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (1,170 )

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses September 30, 2023 December 31, 2022 (in thousands) September 30, 2023 December 31, 2022 Compensation $ 29 $ 1 Professional fees 1,459 492 Clinical trial expenses 127 110 Other expenses 106 203 Accrued expenses $ 1,721 $ 806

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment September 30, 2023 December 31, 2022 (in thousands) September 30, 2023 December 31, 2022 Furniture, fixtures, and equipment 1,555 2,233 Less: accumulated depreciation (1,419 ) (2,038 ) Property and equipment, net $ 136 $ 195

Patents, and Trademark Rights_2

Patents, and Trademark Rights, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents, Trademark Rights	The table below presents the changes in patent and trademark rights (in thousands): Schedule of Patents, Trademark Rights December 31, 2022 $ 1,941 Acquisitions 377 Abandonments and expirations (14 ) Amortization (150 ) September 30, 2023 $ 2,154
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years and thereafter is as follows (in thousands): Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2023 $ 58 2024 225 2025 217 2026 215 2027 194 Thereafter 1,245 Total $ 2,154

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of September 30, 2023 Total Level 1 Level 2 Level 3 Assets: Cash equivalent $ 14,110 $ 14,110 $ — $ — Marketable investments $ 7,167 $ 7,167 $ — $ — As of December 31, 2022 Total Level 1 Level 2 Level 3 Assets: Cash equivalent $ 25,180 $ 25,180 $ — $ — Marketable investments $ 7,137 $ 7,137 $ — $ —
Schedule of Assumptions to Estimate Fair Value of Warrants	The Company utilized the following assumptions to estimate the fair value of the April 2018 Redeemable Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants September 30, 2023 December 31, 2022 Underlying price per share $ 0.46 $ 0.31 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 5.55 % 4.74 % Expected holding period 0.07 0.81 Expected volatility 85 % 75 % Expected dividend yield — — Warrants measurement input — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Redeemable Warrants: September 30, 2023 December 31, 2022 Underlying price per share $ 0.46 $ 0.31 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 5.53 % 4.67 % Expected holding period 0.44 1.19 Expected volatility 80 % 70 % Expected dividend yield — — Warrants measurement input — —
Schedule of Range of Probabilities	Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 %

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Schedule of Operating Lease Future Payments	Future minimum lease payments as of September 30, 2023, are as follows (in thousands): Schedule of Operating Lease Future Payments Year Ending December 31, 2023 $ 73 2024 264 2025 221 2026 200 2027 133 Less imputed interest (141 ) Total $ 750

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	2,763,020	2,445,805

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period	2,019,551	2,020,214
Weighted Average Exercise Price Outstanding, Beginning of Period	$ 3.01	$ 3.01
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 4 months 9 days	8 years 10 months 9 days
Aggregate Intrinsic Value Outstanding, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Options, Expired	(11,113)	(11,776)
Weighted Average Exercise Price, Expired	$ 2.90	$ 2.90
Weighted Average Remaining Contracted Term (years) Expired	8 years 4 months 28 days	8 years 4 months 28 days
Aggregate Intrinsic Value, Expired
Number of Options Outstanding, Ending of Period	2,008,438	2,008,438
Weighted Average Exercise Price Outstanding, End of Period	$ 2.90	$ 2.90
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 4 months 28 days	8 years 4 months 28 days
Aggregate Intrinsic Value Outstanding, Ending of Period
Number of Options, Vested and Expected to Vest	2,008,438	2,008,438
Weighted Average Exercise Price, Vested and Expected to Vest	$ 2.90	$ 2.90
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 4 months 28 days	8 years 4 months 28 days
Aggregate Intrinsic Value, Vested and Expected to Vest
Number of Options Exercisable, End of Period	1,941,772	1,941,772
Weighted Average Exercise Price Exercisable, Ending of Period	$ 1.98	$ 1.98
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	6 years 6 months 7 days	6 years 6 months 7 days
Aggregate Intrinsic Value, Exercisable at End of Period
Weighted Average Remaining Contracted Term (years) Expired		12 years 9 months 21 days
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period	579,032	579,155
Weighted Average Exercise Price Outstanding, Beginning of Period	$ 3.09	$ 3.09
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 4 months 9 days	7 years 11 months 4 days
Aggregate Intrinsic Value Outstanding, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Options, Expired	(53,977)	(54,100)
Weighted Average Exercise Price, Expired	$ 1.62	$ 1.62
Weighted Average Remaining Contracted Term (years) Expired	8 years 8 months 1 day	8 years 8 months 1 day
Number of Options Outstanding, Ending of Period	525,055	525,055
Weighted Average Exercise Price Outstanding, End of Period	$ 1.62	$ 1.62
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 8 months 1 day	8 years 8 months 1 day
Aggregate Intrinsic Value Outstanding, Ending of Period
Number of Options, Vested and Expected to Vest	525,055	525,055
Weighted Average Exercise Price, Vested and Expected to Vest	$ 1.62	$ 1.62
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 8 months 1 day	8 years 8 months 1 day
Aggregate Intrinsic Value, Vested and Expected to Vest
Number of Options Exercisable, End of Period	458,388	458,388
Weighted Average Exercise Price Exercisable, Ending of Period	$ 2.99	$ 2.99
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	10 years 1 month 28 days	10 years 1 month 28 days
Aggregate Intrinsic Value, Exercisable at End of Period
Aggregate Intrinsic Value, Expired
Weighted Average Remaining Contracted Term (years) Expired		8 years 8 months 1 day

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period		561,104
Number of Options, Granted		0	300,000
Number of Options Unvested, End of Period	133,333	133,333
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	166,664	392,326
Weighted Average Exercise Price Unvested, Beginning of Period	$ 9.17	$ 0.80
Average Remaining Contractual Term (years) Unvested, Beginning of Period	6 years 4 months 28 days	8 years 10 months 9 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired	(11,111)	(11,776)
Weighted Average Exercise Price, Expired	$ 2.90	$ 2.90
Weighted Average Remaining Contracted Term (years) Expired	8 years 4 months 28 days	8 years 4 months 28 days
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(88,887)	(313,884)
Weighted Average Exercise Price, Vested	$ 1.98	$ 1.98
Weighted Average Remaining Contracted Term (years) Vested	6 years 6 months 7 days	6 years 6 months 7 days
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	66,666	66,666
Weighted Average Exercise Price Unvested, Ending of Period	$ 14.60	$ 14.60
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	17 years 14 days	17 years 14 days
Aggregate Intrinsic Value Unvested, End of Period
Number of Options, Vested	88,887	313,884
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	66,666	166,789
Weighted Average Exercise Price Unvested, Beginning of Period	$ 9.45	$ 4.05
Average Remaining Contractual Term (years) Unvested, Beginning of Period	4 years 7 months 2 days	9 years 5 months 26 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired	(54,100)	(54,223)
Weighted Average Exercise Price, Expired	$ 1.62
Weighted Average Remaining Contracted Term (years) Expired	8 years 8 months 1 day	8 years 8 months 1 day
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(54,101)	(45,899)
Weighted Average Exercise Price, Vested	$ 2.99	$ 2.99
Weighted Average Remaining Contracted Term (years) Vested	10 years 1 month 28 days	10 years 1 month 28 days
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	66,667	66,667
Weighted Average Exercise Price Unvested, Ending of Period	$ 6.75	$ 6.75
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	4 years 3 months 10 days	4 years 3 months 10 days
Aggregate Intrinsic Value Unvested, End of Period
Number of Options, Vested	54,101	45,899
Number of Options, Expired		1.62

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jan. 28, 2019

Nov. 14, 2018

Oct. 17, 2018

Sep. 12, 2018

Aug. 31, 2020

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Dec. 31, 2021

Jul. 01, 2023

Jan. 01, 2023

Jul. 01, 2022

Jul. 01, 2021

Jul. 01, 2020

Jul. 01, 2019

Sep. 13, 2018

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

0

300,000

Share based compensation expense

$ 182,000

$ 792,000

Unrecognized stock-based compensation cost

$ 35,000

$ 179,000

$ 35,000

$ 179,000

Share-Based Payment Arrangement, Nonemployee [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

Exercise price range

Share based compensation expense

$ 50,000

$ 275,000

2018 Equity Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of stock is reserved for potential issuance

7,000,000

10,865,336

250,000

Number of stock is reserved for potential issuance

968,389

960,976

956,660

685,012

44,299

Option vested years

10 years

10 years

Options, granted

26,324

Exercise price range

$ 9.68

2018 Equity Incentive Plan [Member] | Employees [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

23

Exercise price range

$ 9.68

Expiration period

10 years

2018 Equity Incentive Plan [Member] | Officers [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

27,570

400,000

Exercise price range

$ 9.68

Expiration period

10 years

10 years

2018 Equity Incentive Plan [Member] | Officers [Member] | Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Exercise price range

$ 2.77

2018 Equity Incentive Plan [Member] | Officers [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Exercise price range

$ 3.07

2018 Equity Incentive Plan [Member] | Employees [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

613,512

Expiration period

10 years

10 years

2018 Equity Incentive Plan [Member] | Employees [Member] | Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

1.11

2018 Equity Incentive Plan [Member] | Employees [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Exercise price range

$ 1.71

2018 Equity Incentive Plan [Member] | Officers Directors And Consultants [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

0

850,000

2018 Equity Incentive Plan [Member] | Officers Directors And Consultants [Member] | Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

0.31

2018 Equity Incentive Plan [Member] | Officers Directors And Consultants [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Exercise price range

$ 0.71

Schedule of Available of Sale (

Schedule of Available of Sale (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Fair Value	$ 7,167	$ 7,137
Short-Term Investments	7,167	7,137
Mutual Funds [Member]
Marketable Securities [Line Items]
Fair Value	7,167	7,137
Short-Term Investments	$ 7,167	$ 7,137

Schedule of Equity Securities (

Schedule of Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Net gain recognized during the period on equity securities	$ (309)	$ (365)	$ (201)	$ (1,768)
Net gains and losses recognized during the period on equity securities sold during the period	(42)	(15)	(130)	(598)
Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date	$ (267)	$ (350)	$ (71)	$ (1,170)

Marketable Investments (Details

Marketable Investments (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Held value of marketable securities	$ 7,167,000	$ 7,137,000

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Compensation	$ 29	$ 1
Professional fees	1,459	492
Clinical trial expenses	127	110
Other expenses	106	203
Accrued expenses	$ 1,721	$ 806

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Furniture, fixtures, and equipment	$ 1,555	$ 2,233
Less: accumulated depreciation	(1,419)	(2,038)
Property and equipment, net	$ 136	$ 195

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 30,000	$ 29,000

Schedule of Patents, Trademark

Schedule of Patents, Trademark Rights (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Balance	$ 1,941
Acquisitions	377
Abandonments	(14)
Amortization	(150)	$ (57)
Balance	$ 2,154

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 58
2024	225
2025	217
2026	215
2027	194
Thereafter	1,245
Total	$ 2,154	$ 1,941

Patents, and Trademark Rights_3

Patents, and Trademark Rights, Net (Details Narrative)	Sep. 30, 2023
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, estimated useful life	17 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, estimated useful life	10 years

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 19, 2023	Jul. 07, 2020	Mar. 31, 2020	Sep. 27, 2019	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2020	Dec. 31, 2023	May 10, 2023	May 09, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized					5,000,000		5,000,000						5,000,000
Preferred stock stated value					$ 0.01		$ 0.01						$ 0.01
Preferred stock conversion price					$ 0.20		$ 0.20
Common stock, shares authorized					350,000,000		350,000,000						350,000,000
Common stock specific limitations and restrictions on usage					8,000,000		8,000,000
Common stock, shares issued					48,797,450		48,797,450						48,084,287
Common stock, shares outstanding					48,797,450		48,797,450						48,084,287
Common stock shares issued, value					$ 233,000	$ 25,000	$ 338,000	$ 80,000
Shares sold							327,055
Proceeds from Issuance or Sale of Equity							$ 338,000	$ 80,000
Warrant gross proceeds			$ 264,000
Warrant modification			$ 46,000
Warrant outstanding					15,000		15,000
Sale of Stock, Percentage of Ownership after Transaction	3%
Gross proceeds from issuance of common stock							$ 209,000
Debt Instrument, Interest Rate, Stated Percentage					3%		3%
Debt Instrument, Fee Amount					$ 6,271		$ 6,271
Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Exercise price				$ 0.001
Shares issued price per share				$ 0.899
Percentage of outstanding stock				4.99%
Pre-funded warrants exercised									1,870,000
Warrant [Member]
Class of Stock [Line Items]
Exercise price				$ 0.99
Pre-funded warrants exercised									8,873,960
Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Shares sold				1,740,550
Warrants issued				7,148,310
Proceeds from Issuance or Sale of Equity				$ 7,200,000
Alliance Global Partners, LLC [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants exercised aggregate				8,888,860
Alliance Global Partners, LLC [Member] | Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Shares issued price per share				$ 0.90
Maxim Group LLC [Member]
Class of Stock [Line Items]
Common stock shares issued, value	$ 8,500,000
Maximum [Member] | Alliance Global Partners, LLC [Member] | Representative Warrants [Member]
Class of Stock [Line Items]
Warrants exercised aggregate			266,665	266,665
Directors, Officers and Employees [Member]
Class of Stock [Line Items]
Common stock shares issued, value		$ 500,000
Rights [Member]
Class of Stock [Line Items]
Exercise price					$ 1,000		$ 1,000
Proceeds from warrants							$ 4,700,000
Warrant [Member]
Class of Stock [Line Items]
Exercise price					$ 8.80		$ 8.80
Warrants and rights outstanding term					5 years		5 years
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					4,000,000		4,000,000				4,000,000	250,000	250,000
Preferred stock stated value					$ 0.001		$ 0.001						$ 0.001
Preferred stock, shares outstanding
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					10,000		10,000			10,000
Preferred stock stated value					$ 1,000		$ 1,000						$ 1,000
Conversion of common stock							6
Preferred stock, shares outstanding					690		690						696
Series B Convertible Preferred Stock [Member] | Rights [Member]
Class of Stock [Line Items]
Preferred stock face value					$ 1,000		$ 1,000
Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares to be issued on conversion					114		114
Common Stock [Member]
Class of Stock [Line Items]
Shares sold							385,424	87,045
Proceeds from issuance of common stock							$ 135,000	$ 80,000
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Shares issued price per share					$ 0.31	$ 0.72	$ 0.31	$ 0.72
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Shares issued price per share					$ 0.67	$ 1.02	$ 0.67	$ 1.02
Board [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					5,000,000		5,000,000
Preferred stock stated value					$ 0.01		$ 0.01

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalent-Marketable investments	$ 14,110	$ 25,180
Marketable securities	7,167	7,137
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalent-Marketable investments	14,110	25,180
Marketable securities	7,167	7,137
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalent-Marketable investments
Marketable securities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalent-Marketable investments
Marketable securities

Schedule of Assumptions to Esti

Schedule of Assumptions to Estimate Fair Value of Warrants (Details)	Sep. 30, 2023 $ / shares	Dec. 31, 2022 $ / shares
April 2018 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 0.46	$ 0.31
April 2018 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	17.16	17.16
April 2018 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	5.55	4.74
April 2018 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	25 days	9 months 21 days
April 2018 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	85	75
April 2018 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input
March 2019 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 0.46	$ 0.31
March 2019 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	8.80	8.80
March 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	5.53	4.67
March 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	5 months 8 days	1 year 2 months 8 days
March 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	80	70
March 2019 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input

Schedule of Range of Probabilit

Schedule of Range of Probabilities (Details)	9 Months Ended
	Sep. 30, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	0.50%
Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	1%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%

Fair Value (Details Narrative)

Fair Value (Details Narrative)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Percentage of probability	5%
Floor rate used as proxy for future volatility percentage	100%

Schedule of Operating Lease Fut

Schedule of Operating Lease Future Payments (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Leases
2023	$ 73,000
2024	264,000
2025	221,000
2026	200,000
2027	133,000
Less imputed interest	(141,000)
Total	$ 750,000	$ 837,000

Leases (Details Narrative)

Leases (Details Narrative)									9 Months Ended		12 Months Ended
	Oct. 06, 2023 USD ($)	Dec. 09, 2022 USD ($) ft²	Oct. 05, 2022 USD ($)	Jun. 16, 2022 USD ($) ft²	Feb. 17, 2022 USD ($)	Sep. 14, 2020 USD ($)	May 01, 2019 USD ($) ft²	Jun. 13, 2018 USD ($) ft²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Rent expense									$ 230,000	$ 75,000
Weighted average remaining term									43 months		42 months
Incremental borrowing rate									10%		10%
Right of use asset									$ 727,000		$ 829,000
Lease liability									750,000		$ 837,000
Short term lease rent expense									$ 198,000	$ 8,000
Lease Agreement [Member]
Lease agreement term		2 years		5 years			3 years	6 years
Lease commenced date	May 01, 2024	Apr. 01, 2023	May 01, 2023	Jul. 01, 2022			May 01, 2019	Jul. 01, 2018
Base rent per month						$ 1,415	$ 2,500
Rentable area | ft²		470		5,210			3,000	3,000
Percentage of base rent		6%		3%				3%
Rent expense	$ 3,000		$ 2,850
Lease Agreement [Member] | First Year [Member]
Base rent per month								$ 2,100
Operating Leases, Rent Expense, Net		$ 1,645		$ 15,630
Lease Agreement [Member] | Sixth Year [Member]
Base rent per month								$ 2,785
Lease Agreement [Member] | Fifth Year [Member]
Base rent per month				$ 18,118
Lease Agreement [Member] | Second Year [Member]
Base rent per month		$ 1,744
Lease Agreement [Member] | Fraser Advanced Information Systems [Member]
Lease agreement term						5 years
Lease commenced date						Sep. 14, 2020
Lease Agreement [Member] | Canon Copier [Member]
Lease agreement term					2 years
Lease commenced date					Mar. 01, 2022
Base rent per month					$ 322
Minimum [Member]
Operating lease term									1 year
Operating lease, remaining lease term									9 months
Maximum [Member]
Operating lease term									5 years
Operating lease, remaining lease term									50 months

Research, Consulting and Supp_2

Research, Consulting and Supply Agreements (Details Narrative)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 13, 2022 USD ($)

Jun. 13, 2022 USD ($)

Apr. 30, 2022 USD ($)

Sep. 30, 2023 USD ($)

Sep. 30, 2022 USD ($)

Mar. 31, 2022 USD ($)

Sep. 30, 2023 USD ($)

Sep. 30, 2022 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2017 Integer

Mar. 31, 2023 USD ($)

Research and development expense

$ 2,734,000

$ 1,372,000

$ 7,739,000

$ 4,883,000

Amarex Clinical Research LLC [Member]

Research and development expense

$ 6,400,000

1,266,800

Research and development expense

$ 8,400,000

Development cost

$ 125,470

$ 1,000,000

Estimated lives

4 years 7 months 6 days

Invigilators cost

$ 4,400,000

Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member]

Research and development expense

350,600

Amarex Clinical Research LLC [Member] | Post COVID [Member]

Research and development expense

916,200

HVIVO Services Limited [Member] | Reservation and Start Up Agreement [Member]

Research and development expense

$ 2,340,000

Cancellation fees

$ 60,000

Impatients NV [Member] | Research Consulting and Supply Agreements [Member]

Research and development expense

31,100

Jubilant Hollister Stier [Member]

Research and development expense | Integer

16,000

Research and development expense

$ 1,432,257

Jubilant Hollister Stier [Member] | Research Consulting and Supply Agreements [Member]

Research and development expense

1,432,300

Pharmaceutics International, Inc [Member]

Research and development expense

$ 278,000

Pharmaceutics International, Inc [Member] | Research Consulting and Supply Agreements [Member]

Research and development expense

55,400

Polysciences Inc [Member]

Research and consulting

$ 250,000

Polysciences Inc [Member] | Research Consulting and Supply Agreements [Member]

Research and development expense

0

Yamasa Corporation [Member]

Research and development expense

$ 327,730

Yamasa Corporation [Member] | Research Consulting and Supply Agreements [Member]

Research and development expense

0

Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]

Research and development expense

$ 357,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) $ in Thousands	Oct. 26, 2023 USD ($)
Employees [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, Employee Stock Ownership Plan	$ 500,000